News

Filter

Current filters:

MedImmune

1 to 9 of 39 results

AstraZeneca unit in deal with Omnis Pharma for oncolytic viruses in immuno-oncology

15-01-2015

Anglo-Swedish pharma major AstraZeneca’s biologics R&D subsidiary MedImmune has entered into a licensing…

AstraZenecaBiotechnologyLicensingMedImmuneOmnis PharmaceuticalsOncology

AstraZeneca to invest $200 million in expanding US biologics manufacturing center

22-11-2014

Anglo-Swedish pharma major AstraZeneca on Friday unveiled plants to expand its biologics manufacturing…

AstraZenecaBiotechnologyFinancialMedImmuneProductionUSA

MedImmune to acquire company to strengthen focus on biomarkers in immuno-oncology

MedImmune to acquire company to strengthen focus on biomarkers in immuno-oncology

04-11-2014

MedImmune, a US subsidiary of Anglo-Swedish pharma major AstraZeneca has entered into an agreement to…

AstraZenecaDefiniensMedImmuneMergers & AcquisitionsOncologyPharmaceutical

MedImmune and Shionogi sign license agreement for Shionogi's preclinical biologics in acute coronary syndrome

MedImmune and Shionogi sign license agreement for Shionogi's preclinical biologics in acute coronary syndrome

09-10-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

BiotechnologyCardio-vascularCrestorJapanLicensingMedImmuneShionogi

Nicox partners with OptiMed for distribution of its portfolio in Australia and New Zealand

Nicox partners with OptiMed for distribution of its portfolio in Australia and New Zealand

09-10-2014

International ophthalmic company Nicox has entered into an exclusive licensing agreement with Australian…

AdenoPlusAustraliaLicensingMedImmuneNew ZealandNicOxOphthalmicsPharmaceuticalXailin

AstraZeneca's Medimmune to collaborate on new oncology biologics lab with Cancer Research UK

AstraZeneca's Medimmune to collaborate on new oncology biologics lab with Cancer Research UK

25-09-2014

Medimmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

BiotechnologyCancer Research TechnologyCancer Research UKMedImmuneOncologyResearchUK

FDA fast track designation for AstraZeneca’s MEDI3902

FDA fast track designation for AstraZeneca’s MEDI3902

24-09-2014

Anglo-Swedish pharma major AstraZeneca’s global biologics R&D arm, MedImmune has received fast track…

Antibiotics and Infectious diseasesAstraZenecaBiotechnologyMEDI3902MedImmuneRegulationUSA

1 to 9 of 39 results

COMPANY SPOTLIGHT

Menarini

Back to top